dissatisfact
result
antivir
therapi
chronic
hepat
c
fuel
continu
research
effect
toler
regimen
debat
recent
focus
possibl
use
amantadin
ama
agent
direct
activ
rna
virus
enhanc
effect
interferon
two
paper
add
controversi
ama
tricycl
amin
relat
analogu
rimantadin
rima
antivir
activ
toga
myxo
arena
flavi
coronavirus
inhibit
influenza
viru
replic
obtain
drug
exploit
clinic
prevent
cure
flu
known
mechan
action
ama
includ
inhibit
earli
step
viral
replic
like
viral
uncoat
interact
influenza
viral
matrix
protein
import
virion
bud
jp
smith
report
pilot
studi
patient
chronic
hepat
c
fail
previou
monotherapi
ainterferon
ifn
ama
effect
reduc
necroinflamm
patient
decreas
aminotransferas
therapi
six
patient
normal
alanin
aminotransferas
alt
neg
hepat
c
viru
hcv
rna
end
therapi
four
sustain
respons
sr
effect
tricycl
amin
antivir
agent
hcv
challeng
subsequ
trial
ama
rima
nonrespond
ifn
patient
studi
shown
almost
uniformli
reduct
alt
rang
patient
therapi
consist
effect
hcvrna
sr
ama
monotherapi
never
report
origin
studi
behaviour
ama
similar
ribavirin
monotherapi
often
improv
liver
biochemistri
significantli
reduc
hcv
viral
load
absenc
suitabl
cellular
model
hcv
replic
hamper
vitro
evalu
ama
rima
indirect
assess
effect
hcv
proteas
helicas
atpas
rnadepend
rna
polymeras
hcv
intern
ribosom
entri
site
ire
translat
perform
vitro
biochem
assay
inhibit
observ
concentr
mgml
iresspecif
inhibit
seen
clinic
relev
concentr
cap
ire
report
gene
suppress
higher
level
possibl
nonspecif
translat
inhibit
experi
allow
conclud
ama
rima
direct
specif
inhibitori
effect
hcv
nonstructur
protein
ire
vitro
mammalian
binari
express
system
abl
synthes
posit
neg
strand
hcvrna
recent
use
determin
whether
ifn
ribavirin
ama
directli
inhibit
hcv
replic
replicon
system
induc
doserespons
inhibit
hcv
strand
synthesi
without
affect
actin
bgalactosidas
mrna
level
dose
produc
complet
inhibit
hcv
protein
synthesi
ribavirin
ama
dose
pharmacolog
concentr
effect
hcv
rna
level
thu
ifn
act
directli
antihcv
agent
ribavirin
ama
action
hcv
like
indirect
like
ribavirin
ama
rima
may
act
also
immun
system
effect
ama
alon
combin
studi
cultur
pbmc
chronic
hepat
c
patient
ten
control
four
patient
hcv
core
prolif
respons
ama
suppress
respons
case
antiprolif
effect
greater
ifn
pbmc
cultur
patient
hcvrna
posit
ama
alon
combin
ifn
dosedepend
reduc
hcvrna
content
ama
alon
ifn
alon
combin
pbmc
cultur
becam
hcvrna
neg
respect
contrast
ifn
ama
modifi
express
oa
spontan
mitogenstimul
product
gifn
interleukin
ama
rima
thu
weak
antivir
provid
antiinflammatori
activ
lack
potent
direct
inhibitor
hcv
replic
suitabl
clinic
use
nonetheless
stimul
studi
aim
evalu
potenti
combin
therapi
ifn
ama
nonrespond
ifn
ifn
ribavirin
patient
mani
control
uncontrol
trial
progress
two
recent
report
trial
reach
contrast
result
zeuzem
colleagu
studi
subject
chronic
hepat
c
randomli
alloc
mu
tiw
week
mu
tiw
anoth
week
plu
ama
sulphat
mg
twice
daili
po
week
ifn
regimen
plu
placebo
virolog
endoftreat
respons
etr
observ
patient
treat
combin
therapi
monotherapi
sr
occur
respect
mangia
colleagu
enrol
patient
random
week
treatment
mu
tiw
week
without
ama
hydrochlorid
mg
twice
daili
report
optimist
find
rate
etr
studi
combin
monotherapi
importantli
sr
vs
respect
interestingli
studi
addit
ama
affect
safeti
toler
profil
ifn
healthrel
qualiti
life
seemingli
improv
term
fatigu
vigour
score
antidepress
action
ama
even
account
differ
among
trial
ifn
schedul
distribut
hcv
genotyp
rate
advanc
fibrosi
strong
determin
low
respons
ifn
difficult
reconcil
discord
result
trial
scarc
inform
deriv
studi
mani
confoundingli
small
sampl
size
report
abstract
two
larg
studi
add
relev
element
pattern
first
ref
produc
cooper
uk
group
small
pilot
trial
one
centr
involv
total
patient
pilot
multicentr
studi
cirrhosi
unusu
low
genotyp
random
receiv
mu
tiw
week
without
ama
hydrochlorid
mg
twice
daili
etr
rate
combin
monotherapi
sr
rate
respect
studi
multicentr
italian
trial
without
cirrhosi
random
mu
tiw
week
mu
tiw
anoth
week
without
ama
hydrochlorid
mg
twice
daili
week
result
uninspir
etr
combin
monotherapi
sr
vs
neg
effect
genotyp
respons
seen
two
studi
reiter
find
zeuzem
mangia
ama
anoth
fail
promis
possibl
case
still
open
interest
find
studi
month
treatment
patient
combin
significantli
like
hcvrna
neg
vs
uk
studi
vs
italian
studi
figur
consist
higher
etr
suggest
initi
addit
effect
ama
exist
help
reduc
temporarili
viral
load
undetect
level
weak
effect
lost
possibl
viral
escap
mutat
still
treatment
thu
bring
final
result
level
ifn
monotherapi
similar
trial
still
underway
observ
phenomenon
found
reduct
heterogen
reemerg
quasispeci
subject
breakthrough
di
marco
unpublish
data
ama
thu
probabl
antihcv
effect
readili
induc
viral
resist
lead
loss
efficaci
discard
feebl
antivir
activ
ama
rima
patient
ama
alreadi
loser
combin
ifn
compar
standard
ifnribavirin
schedul
rate
sr
pegyl
ifn
whose
rate
success
goe
even
ahead
cours
ad
ama
combin
regimen
standard
ifn
probabl
unsuccess
fact
interim
analysi
week
induct
therapi
daili
highdos
combin
ribavirin
ama
shown
increas
respons
rate
issu
threedrug
combin
regimen
could
promis
nonrespond
ifn
ifn
plu
ribavirin
brillanti
recent
publish
random
control
trial
includ
patient
chronic
hepat
c
nonrespond
previou
cours
ifn
forti
receiv
dose
mu
altern
day
ribavirin
mg
daili
ama
mg
daili
month
treatment
without
ama
month
followup
patient
treat
tripl
doubl
therapi
achiev
sr
convers
teuber
colleagu
report
neg
result
german
multicentr
studi
evalu
efficaci
tripl
therapi
vs
ifn
ribavirin
combin
ifn
nonrespond
ifn
given
induct
mu
daili
first
week
follow
mu
tiw
week
mu
tiw
week
sr
rate
significantli
higher
patient
receiv
tripl
therapi
ifnribavirin
vs
studi
tripl
therapi
without
ifn
induct
smaller
seri
nonrespond
relaps
ifn
monotherapi
would
suggest
ad
ama
recov
signific
amount
sustain
respons
unknown
whether
slight
advantag
observ
ama
viral
clearanc
rate
month
also
exist
nonrespond
difficult
explain
studi
differ
conclus
besid
intrins
differ
schedul
select
patient
remind
definit
nonrespons
ifn
monotherapi
clearcut
respons
partial
respond
breakthrough
patient
intrins
interferon
sensit
may
includ
differ
rate
trial
moreov
would
relev
know
ama
help
retreat
nonrespond
ifnribavirin
like
much
tougher
client
pegyl
ifn
peg
go
futur
standard
need
inform
combin
ama
data
earli
kinet
respons
peg
ama
provid
patient
relaps
herrin
et
al
digest
diseas
week
atlanta
ga
nonrespond
afdahl
et
al
digest
diseas
week
atlanta
ga
ifnribavirin
week
peg
ama
clear
hcvrna
relaps
nonrespond
patient
peg
riba
induc
clearanc
relaps
nonrespond
tripl
therapi
peg
riba
ama
appar
effect
obtain
negativ
hcvrna
relaps
nonrespond
patient
thu
proport
patient
sensit
ifn
ama
seem
enhanc
effect
combin
peg
ribavirin
albeit
scarc
effect
final
question
mark
remain
first
even
random
studi
essenti
neg
result
term
sr
show
nonsignific
trend
favour
ama
studi
sampl
size
may
inadequ
exclud
type
b
fals
neg
error
pool
individu
patient
data
among
trial
underway
order
perform
metaanalysi
conclus
solv
issu
trial
use
fix
dose
ama
seemingli
deriv
use
neurolog
rather
evid
antivir
activ
dosefind
trial
could
use
explor
possibl
underdos
theoret
could
affect
effect
drug
trial
perform
popul
higher
mean
bodi
mass
index
hcv
replicon
model
could
also
help
sort
vitro
right
amount
drug
formul
ama
use
could
relev
studi
report
posit
result
use
ama
hydrochlorid
neg
german
trial
perform
ama
sulphat
bioavail
pharmacokinet
pharmacodynam
properti
ama
hydrochlorid
sulphat
equival
line
much
less
exploit
rima
equival
ama
sum
lowcost
highli
toler
drug
somehow
defeat
initi
promis
efficaci
hcv
part
disappoint
may
due
rel
high
level
efficaci
reach
current
combin
schedul
given
current
shortag
promis
altern
give
ama
would
wise
reexplor
clinic
potenti
combin
pegyl
ifn
ribavirin
nonrespond
use
cohort
patient
suffici
larg
analyz
predictor
effect
search
better
antivir
drug
still
